Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: Implications for therapy of cutaneous T-cell lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1970-1979

  Wysocka, Maria ^a   Dawany, Noor ^b   Benoit, Bernice ^a   Kossenkov, Andrew V ^b   Troxel, Andrea B ^c   Gelfand, Joel M ^a   Sell, Michael Kelly ^a   Showe, Louise C ^b   Rook, Alain H ^a  

^a Department of Dermatology ^*  (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CTCL; IFN ; immunotherapy; IRF 8; TLR7 8 agonist

Indexed keywords

3M 007; ALPHA INTERFERON; IMIDAZOQUINOLINE 007; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 12P35; INTERLEUKIN 12P40; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 15; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALPHA CHAIN; ARTICLE; BETA CHAIN; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; MICROARRAY ANALYSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEZARY SYNDROME; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, T-CELL, CUTANEOUS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 80053200459     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.582202     Document Type: Article

References (53)

1. Haynes BF, Bunn P, Mann D, et al. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. J Clin Invest 1981;67:523-530. (Pubitemid 11141735)
2. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996;88:2385-2409. (Pubitemid 26327487)
3. Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Primary cutaneous aggressive epidermotropic CD8p T cell lymphoma. J Am Acad Dermatol 2010;62:300-307.
4. Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH. Association of change in clinical status and change in the percentage of the CD4pCD267 lymphocyte population in patients with Sezary syndrome. J Am Acad Dermatol. 2005;53:428-434. (Pubitemid 41195963)
5. Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol 2006;33(Suppl. 1):27-42.
6. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary T cells. Arch Dermatol 1993;129:486-489. (Pubitemid 23118249)
7. Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH. Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 1999;163:4073-4079. (Pubitemid 29450939)
8. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-94.
9. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994;103:669-673. (Pubitemid 24350134)
10. Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006;107: 3189-3196.
11. Wysocka M, Zaki MH, French LE, et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002;100:3287-3294. (Pubitemid 35217079)
12. Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004;104:4142-4149. (Pubitemid 39620167)
13. Yamanaka K, Yawalkar N, Jones DA, et al. Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma. Clin Cancer Res 2005;11:5748-5755. (Pubitemid 41170299)
14. Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of Tcell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003;102:4059-4066. (Pubitemid 37486989)
15. Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Invest Dermatol 1995;105(1 Suppl.):105S-109S.
16. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-908. (Pubitemid 29361820)
17. Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome. Clin Lymphoma Myeloma 2006;7:226-232. (Pubitemid 44823808)
18. Rook AH, Junkins-Hopkins JM,McGinnis KS, et al. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Adv Dermatol 2002;18:29-43.
19. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009;21:131-137.
20. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003;17:1435-1448, ix. (Pubitemid 37523679)
21. Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002;195:1507-1512. (Pubitemid 34602828)
22. Wysocka M, Newton S, Benoit BM, et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 2007;7:524-534. (Pubitemid 350043490)
23. Murphy GF. Cutaneous T-cell lymphoma. Adv Pathol 1988;1:131-156.
24. Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491-1498.
25. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259-1268.
26. Showe MK, Vachani A, Kossenkov AV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009;69:9202-9210.
27. Abbas AR, Baldwin D, Ma Y, et al. Immune Response In Silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 2005;6:319-331. (Pubitemid 40903405)
28. Abrams JT, Lessin S, Ghosh SK, et al. A clonal CD4-positive T-cell line established from the blood of a patient with Sezary syndrome. J Invest Dermatol 1991;96:31-37.
29. Kawai T, Sato S, Ishii KJ, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061-1068. (Pubitemid 41057726)
30. Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J Immunol 2003;170:1131-1135. (Pubitemid 36139475)
31. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-15550. (Pubitemid 41528093)
32. Bouaziz JD, Ortonne N, Giustiniani J, et al. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients. J Invest Dermatol 2005;125:1273-1278.
33. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-776. (Pubitemid 43090462)
34. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243. (Pubitemid 128678837)
35. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000;192:219-226.
36. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516-523. (Pubitemid 36975769)
37. Hermann P, Rubio M, Nakajima T, Delespesse G, Sarfati M. IFN-alpha priming of human monocytes differentially regulates gram-positive and gram-negative bacteria-induced IL-10 release and selectively enhances IL-12p70, CD80, and MHC class I expression. J Immunol 1998;161:2011-2018. (Pubitemid 28387627)
38. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041-1048. (Pubitemid 23260442)
39. Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-amma of lipopolysaccharide- inducible p35 and p40 genes. Blood 1995;86:646-650.
40. Libraty DH, Airan LE, Uyemura K, et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest 1997;99:336-341. (Pubitemid 27053473)
41. Hunter CA, Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev 2004;202:106-114. (Pubitemid 39576908)
42. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-242. (Pubitemid 46697908)
43. Honda K, Taniguchi T. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-658. (Pubitemid 44298214)
44. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 2003;24:81-90. (Pubitemid 37324035)
45. Liu J, Guan X, Tamura T, Ozato K, Ma X. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequencebinding protein. J Biol Chem 2004;279:55609-55617. (Pubitemid 40066565)
46. Politis AD, Ozato K, Coligan JE, Vogel SN. Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages. J Immunol 1994;152:2270-2278.
47. Bachem A, Guttler S, Hartung E, et al. Superior antigen cross-presentation and XCR1 expression define human CD11cp CD141p cells as homologues of mouse CD8p dendritic cells. J Exp Med 2010;207:1273-1281.
48. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002;138:1137-1139. (Pubitemid 35025683)
49. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97:1143-1153. (Pubitemid 41511214)
50. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S. Imiquimod is a strong inhibitor of tumor cellinduced angiogenesis. Int J Dermatol 2005;44:14-19. (Pubitemid 40201982)
51. Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol 2006;7:155-169. (Pubitemid 43845340)
52. Martinez-Gonzalez MC, Verea-Hernando MM, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur J Dermatol 2008;18: 148-152. (Pubitemid 351554802)
53. Kim YH, Girardi M, DuvicM, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63:975-983.